[1] GBD 2013 Mortality and Causes of Death Collaborators. Global, regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death,1990-2013:a systematic analysis for the Global Burden of Disease Study 2013. Lancet,2015,385:117-171. [2] Trepo C,Chan HL,Lok A. Hepatitis B virus infection. Lancet,2014,384:2053-2063 . [3] Xu Z,Liu Y,Xu T,et al. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol,2010,48:270-274. [4] Liu Y,Zhong Y,Zou Z,et al. Features and clinical implications of hepatitis B virus genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B. J Clin Virol,2010,47:243-247. [5] 赵琳,黄玲,王晶慧. 240例初治乙型肝炎患者的流行病学特征. 肝脏,2011,16:442-445. [6] Thibault V,Aubron-Olivier C,Agut H,et al. Primary infection with a lamivudine-resistant hepatitis B virus. Aids,2002,16:131-133. [7] 中华医学会传染病与寄生虫病学分会、肝病学分会联合修订. 病毒性肝炎防治方案. 中华肝脏病杂志,2000,8:5-10. [8] Ozasa A,Tanaka Y,Orito E,et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology,2006,44:326-334. [9] Matsuura K,Tanaka Y,Hige S,et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol,2009,47:1476-1483. [10] Yotsuyanagi H, Ito K,Yamada N,et al. High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B. Clin Infect Dis,2013,57:935-942. [11] Yano K,Tamada Y,Yatsuhashi H,et al. Dynamic epidemiology of acute viral hepatitis in Japan. Intervirology,2010,53:70-75. [12] Ito K,Yotsuyanagi H,Yatsuhashi H,et al. Risk factors for long term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology,2014,59:89-97. [13] Li HM,Wang JQ,Wang R,et al. Hepatitis B virus genotypes and genome characteristics in China. World J Gastroenterol,2015,21(21):6684-6697. [14] Chattopadhyay S,Das BC,Hussain Z,et al. Hepatitis B virus genotypes in acute and fulminant hepatitis patients from north India using two different molecular genotyping approaches. Hepatol Res,2006,35:79-82. [15] Suzuki Y,Kobayashi M,Ikeda K,et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol,2005,76:33-39. [16] Hayashi K,Katano Y,Ishigami M,et al. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine resistant strains. J Gastroenterol Hepatol,2010,25:745-749. [17] Baxa DM,Thekdi AD,Golembieski A,et al. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol,2013,58:212-216. [18] Morando F,Rosi S,Fasolato S, et al. Severe acute hepatitis B in a treatment naive patient with antiviral drug resistant mutations in the polymerase gene. J Med Virol,2013,85:210-213. [19] Clements CJ,Coghlan B,Creati M,et al. Global control of hepatitis B virus:does treatment-induced antigenic change affect immunization. Bull World Health Organ,2010,88:66-73. [20] Sainokami S,Abe K,Sato A,et al. Initial load of hepatitis B virus(HBV),its changing profile,and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol,2007,42:241-249. |